I see it as a positive sign when you see companies building their potential, as far as investing in other technologies and adding it to their current portfolio.

This is a loss we could ill afford.

I like the fact that there's consistency in the sector, ... Oracle is saying good things and SAP is saying good things. It's more of the news flow being consistent across the board rather than one [company] saying things look great for next quarter.

(It's) not that expensive when you consider what women shell out over time.

We've only been on the market for about four weeks with the technology. But in a very short time, ... people are going to better understand specifically what we're doing.

Tomorrow's action will be totally affected by the Intel numbers. We're seeing some buying in anticipation of a pickup [in technology spending], and we're starting to see some pockets of it.

I expect the market to do fairly well in the near term, especially as portfolio managers move money out of bonds back into equity. Then things will kind of flatten out.

There is no one formula. Every formula is unique. It really depends on your individual skin as to what we put in. ... Unlike mass products that try to put in a single active ingredient and then try to sell it to everyone, we don't do that at Lab 21.

I commend Selectman McAuliffe and offer full support.